NASDAQ: ADAG

Allist Pharmaceuticals' NDA Accepted by China's CDE for Furmonertinib in Adjuvant NSCLC – Third‑Generation EGFR‑TKI Targets Post‑Resection Patients with Exon 19 Deletion or L858R Mutations
CompanyDrug

Allist Pharmaceuticals’ NDA Accepted by China’s CDE for Furmonertinib in Adjuvant NSCLC – Third‑Generation EGFR‑TKI Targets Post‑Resection Patients with Exon 19 Deletion or L858R Mutations

Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that the New Drug Application (NDA) for a new indication of furmonertinib mesylate tablets has been accepted by the Center for Drug Evaluation…

BoomRay Licenses Preclinical Radioligand Therapy to Novartis in Exclusive Global Deal Worth Up to USD 900 Million – China RDC Specialist Adds Big Pharma Validation

BoomRay Licenses Preclinical Radioligand Therapy to Novartis in Exclusive Global Deal Worth Up to USD 900 Million – China RDC Specialist Adds Big Pharma Validation

Merck's Subcutaneous Pembrolizumab KEYJECT Wins MHLW Approval Across All KEYTRUDA Indications in Japan – Phase III Shows Comparable Exposure and 45% ORR in First-Line Metastatic NSCLC

Merck’s Subcutaneous Pembrolizumab KEYJECT Wins MHLW Approval Across All KEYTRUDA Indications in Japan – Phase III Shows Comparable Exposure and 45% ORR in First-Line Metastatic NSCLC

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Adagene Inc. Presents Positive Interim Results for ADG126 at AACR Annual Meeting

CompanyDrug

Adagene’s ADG126 Shows Promise in Combination with Anti-PD-1 Therapy

CompanyDeals

Adagene Initiates International Study for ADG126 in Hepatocellular Carcinoma

Show More